Targeting Mechanisms of the DNA Damage Response (DDR) and DNA Repair by Natural Compounds to Improve cAT-Triggered Tumor Cell Death

被引:6
作者
Aengenvoort, Jana [1 ]
Sekeres, Marlena [1 ]
Proksch, Peter [2 ]
Fritz, Gerhard [1 ]
机构
[1] Heinrich Heine Univ Dusseldorf, Inst Toxicol, Fac Med, Moorenstr 5, D-40225 Dusseldorf, Germany
[2] Heinrich Heine Univ Dusseldorf, Inst Pharmaceut Biol & Biotechnol, Univ Str 1, D-40225 Dusseldorf, Germany
来源
MOLECULES | 2022年 / 27卷 / 11期
关键词
DNA damage response; DNA repair; natural compounds; cell death; drug resistance; anticancer drugs; MARINE SPONGE METABOLITE; DOUBLE-STRAND BREAKS; COMBINATION THERAPY; PROTEIN-KINASE; CANCER CELLS; IN-VITRO; CISPLATIN; ATR; ARTESUNATE; PHOSPHORYLATION;
D O I
10.3390/molecules27113567
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recently, we identified secalonic acid F (SA), 5-epi-nakijiquinone Q (NQ) and 5-epi-ilimaquinone (IQ) as natural compounds (NC) affecting mechanisms of the DNA damage response (DDR). Here, we further characterized their effects on DDR, DNA repair and cytotoxicity if used in mono- and co-treatment with conventional anticancer therapeutics (cAT) (cisplatin (Cis), doxorubicin (Doxo)) in vitro. All three NC influence the phosphorylation level of selected DDR-related factors (i.e., pCHK1, pKAP1, pP53, pRPA32) in mono- and/or co-treatment. Both SA and NQ attenuate the Cis- and Doxo-induced G2/M-phase arrest and effectively stimulate caspase-mediated apoptosis. Notably, SA impacts DNA repair as reflected by enhanced steady-state levels of Cis-(1,2-GpG)-DNA adducts and Doxo-induced DNA double-strand breaks (DSB). Moreover, SA decreased the mRNA and protein expression of the homologous recombination (HR)-related DSB repair factors RAD51 and BRCA1. Both SA and NQ promote Cis- and Doxo-induced cytotoxicity in an additive to synergistic manner (CI <= 1.0). Summarizing, we conclude that SA promotes cAT-driven caspase-dependent cell death by interfering with DSB repair and DDR-related checkpoint control mechanisms. Hence, SA is considered as the most promising lead compound to evaluate its therapeutic window in forthcoming pre-clinical in vivo studies.
引用
收藏
页数:19
相关论文
共 72 条
  • [1] The Aurora-B-dependent NoCut checkpoint prevents damage of anaphase bridges after DNA replication stress
    Amaral, Nuno
    Vendrell, Alexandre
    Funaya, Charlotta
    Idrissi, Fatima-Zahra
    Maier, Michael
    Kumar, Arun
    Neurohr, Gabriel
    Colomina, Neus
    Torres-Rosell, Jordi
    Geli, Maria-Isabel
    Mendoza, Manuel
    [J]. NATURE CELL BIOLOGY, 2016, 18 (05) : 516 - +
  • [2] Natural products in drug discovery: advances and opportunities
    Atanasov, Atanas G.
    Zotchev, Sergey B.
    Dirsch, Verena M.
    Supuran, Claudiu T.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2021, 20 (03) : 200 - 216
  • [3] Balancing life-or-death decisions
    Bartek, Jiri
    Lukas, Jiri
    [J]. SCIENCE, 2006, 314 (5797) : 261 - 262
  • [4] Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs:: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks
    Batista, Luis F. Z.
    Roos, Wynand P.
    Christmann, Markus
    Menck, Carlos F. M.
    Kaina, Bernd
    [J]. CANCER RESEARCH, 2007, 67 (24) : 11886 - 11895
  • [5] Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
    Bellmunt, J.
    Paz-Ares, L.
    Cuello, M.
    Cecere, F. L.
    Albiol, S.
    Guillem, V.
    Gallardo, E.
    Carles, J.
    Mendez, P.
    de la Cruz, J. J.
    Taron, M.
    Rosell, R.
    Baselga, J.
    [J]. ANNALS OF ONCOLOGY, 2007, 18 (03) : 522 - 528
  • [6] Artesunate Induces Oxidative DNA Damage, Sustained DNA Double-Strand Breaks, and the ATM/ATR Damage Response in Cancer Cells
    Berdelle, Nicole
    Nikolova, Teodora
    Quiros, Steve
    Efferth, Thomas
    Kaina, Bernd
    [J]. MOLECULAR CANCER THERAPEUTICS, 2011, 10 (12) : 2224 - 2233
  • [7] Artesunate enhances the therapeutic response of glioma cells to temozolomide by inhibition of homologous recombination and senescence
    Berte, Nancy
    Lokan, Stefanie
    Eich, Marcus
    Kim, Ella
    Kaina, Bernd
    [J]. ONCOTARGET, 2016, 7 (41) : 67235 - 67250
  • [8] DNA damage response inhibitors: Mechanisms and potential applications in cancer therapy
    Carrassa, Laura
    Damia, Giovanna
    [J]. CANCER TREATMENT REVIEWS, 2017, 60 : 139 - 151
  • [9] Chou T.C, 2009, CANCER RES, V69, P4752
  • [10] Chou TC, 1998, FASEB J, V12, pA143